mitoguazone and Sarcoma

mitoguazone has been researched along with Sarcoma* in 2 studies

Trials

1 trial(s) available for mitoguazone and Sarcoma

ArticleYear
Phase II trial of methylglyoxal-bis-guanylhydrazone (methyl-GAG) in patients with soft-tissue sarcomas.
    American journal of clinical oncology, 1985, Volume: 8, Issue:4

    A phase II study of Methylglyoxal-bis-guanylhydrazone (Methyl-GAG) was conducted on 20 previously treated patients with soft-tissue sarcomas. No major responses were seen among 18 adequately treated patients. Toxicity including severe fatigue, muscle pains, and pharyngitis was noted in most patients. Methyl-GAG does not have significant antitumor activity in previously treated patients with soft-tissue sarcomas.

    Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Mitoguazone; Sarcoma; Soft Tissue Neoplasms

1985

Other Studies

1 other study(ies) available for mitoguazone and Sarcoma

ArticleYear
Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma.
    Investigational new drugs, 1985, Volume: 3, Issue:4

    Patients with objectively measurable soft tissue sarcoma, bone sarcoma, or mesothelioma who had failed at least one prior chemotherapy regimen received either bleomycin (20 U/M2 i.v. day 1 each week), chlorozotocin (150 mg/M2 i.v. q6 weeks), MGBG (500 mg/M2 i.v. each week, escalated in 50 mg/M2 weekly increments to a maximum dose of 700 mg/M2), or bruceantin (5.5 mg/M2 days 1, 8, 15, and 22, with cycles repeated every 6 weeks). One hundred eighty patients were evaluable: 53 on bleomycin, 51 on chlorozotocin, 38 on MGBG, and 38 on bruceantin. Two partial responses resulted from bleomycin, and one each from chlorozotocin and MGBG. Both responders on bleomycin had mesothelioma. Seventy-four percent of the patients were of ECOG performance status 0 or 1, and over half on each arm had moderate or worse toxicity. At these doses and schedules, none of the four drugs tested was active against previously treated sarcomas. Bleomycin, however, should be considered for further evaluation in mesothelioma patients.

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Bleomycin; Bone Neoplasms; Drug Evaluation; Female; Glaucarubin; Humans; Male; Mesothelioma; Middle Aged; Mitoguazone; Phenanthrenes; Quassins; Sarcoma; Soft Tissue Neoplasms; Streptozocin

1985